Hafez, 1,486 patient HCQ late treatment study: 12% faster viral clearance [p=0.59] https://c19p.org/hafez
copied to clipboard
Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
et al., Antibiotics, doi:10.3390/antibiotics11040498
Retrospective hospitalized patients in the United Arab Emirates, showing no significant difference in viral clearance with different combinations of HCQ, AZ, favipiravir, and lopinavir/ritonavir.
|
viral clearance time, 12.3% lower, HR 0.88, p = 0.59, treatment 40, control 1,446, Cox proportional hazards.
|
|
viral clearance time, 58.7% lower, HR 0.41, p = 0.09, treatment 4, control 1,446, HCQ + favipiravir + lopinavir/ritonavir, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Hafez et al., 4/8/2022, retrospective, United Arab Emirates, Middle East, peer-reviewed, 6 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.